B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice
article
OA: closed
CC0
⤵ 21 in-corpus citations
AI-generated summary
Ibrutinib prevented endometriosis progression in mice by shifting activated B cells toward regulatory B cells, while anti-CD20 antibody depletion of B cells had no effect.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
STUDY QUESTION: What are the effects of B lymphocyte inactivation or depletion on the progression of endometriosis? SUMMARY ANSWER: Skewing activated B cells toward regulatory B cells (Bregs) by Bruton's tyrosine kinase (Btk) inhibition using Ibrutinib prevents endometriosis progression in mice while B cell depletion using an anti-CD20 antibody has no effect. WHAT IS KNOWN ALREADY: A polyclonal activation of B cells and the presence of anti-endometrial autoantibodies have been described in a large proportion of women with endometriosis though their exact role in the disease mechanisms remains unclear. STUDY DESIGN, SIZE, DURATION: This study included comparison of endometriosis progression for 21 days in control mice versus animals treated with the anti-CD20 depleting antibody or with the Btk inhibitor Ibrutinib that prevents B cell activation. PARTICIPANTS/MATERIALS, SETTING, METHODS: After syngeneic endometrial transplantation, murine endometriotic lesions were compared between treated and control mice using volume, weight, ultrasonography, histology and target genes expression in lesions. Phenotyping of activated and regulatory B cells, T lymphocytes and macrophages was performed by flow cytometry on isolated spleen and peritoneal cells. Cytokines were assayed by ELISA. MAIN RESULTS AND THE ROLE OF CHANCE: Btk inhibitor Ibrutinib prevented lesion growth, reduced mRNA expression of cyclooxygenase-2, alpha smooth muscle actin and type I collagen in the lesions and skewed activated B cells toward Bregs in the spleen and peritoneal cavity of mice with endometriosis. In addition, the number of M2 macrophages decreased in the peritoneal cavity of Ibrutinib-treated mice compared to anti-CD20 and control mice. Depletion of B cells using an anti-CD20 antibody had no effect on activity and growth of endometriotic lesions and neither on the macrophages, compared to control mice. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: It is still unclear whether B cell depletion by the anti-CD20 or inactivation by Ibrutinib can prevent establishment and/or progression of endometriosis in humans. WIDER IMPLICATIONS OF THE FINDINGS: Further investigation may contribute to clarifying the role of B cell subsets in human endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by a grant of Institut National de la Santé et de la Recherche Médicale and Paris Descartes University. None of the authors has any conflict of interest to disclose.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (38)
- Alteration of Nrf2 and Glutamate Cysteine Ligase expression contribute to lesions growth and fibrogenesis in ectopic endometriosis via openalex
- Anti-endometrial and anti-endothelial auto-antibodies in women with endometriosis via openalex
- Antiendometrial Antibodies in Patients With Endometriosis via openalex
- Dysregulation of the ADAM17/Notch signalling pathways in endometriosis: from oxidative stress to fibrosis via openalex
- Endometriosis, retrograde menstruation and peritoneal inflammation in women and in baboons via openalex
- Evaluation of estrogen in endometriosis patients: Regulation of GATA‐3 in endometrial cells and effects on Th2 cytokines via openalex
- Immunology of endometriosis via openalex
- Increased percentage of Th17 cells in peritoneal fluid is associated with severity of endometriosis via openalex
- Macrophages Are Alternatively Activated in Patients with Endometriosis and Required for Growth and Vascularization of Lesions in a Mouse Model of Disease via openalex
- MAP kinases and the inflammatory signaling cascade as targets for the treatment of endometriosis? via openalex
- Molecular Network Analysis of Endometriosis Reveals a Role for c-Jun–Regulated Macrophage Activation via openalex
- Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? via openalex
- Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity via openalex
- Role of the protein kinase BRAF in the pathogenesis of endometriosis via openalex
- The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model via openalex
- The role of the B lymphocytes in endometriosis: A systematic review via openalex
- Time to redefine endometriosis including its pro-fibrotic nature via openalex
- W2394989709 via openalex
- W2734526350 via openalex
- W2766697888 via openalex
- W4211081176 via openalex
- W6747181971 via openalex
- W1735859738 via openalex
- W1983395516 via openalex
- W2006236831 via openalex
- W2024104456 via openalex
- W2029503621 via openalex
- W2031500443 via openalex
- W2046304104 via openalex
- W2064862416 via openalex
- W2075875145 via openalex
- W2089103836 via openalex
- W2118994799 via openalex
- W2131697342 via openalex
- W2143436758 via openalex
- W2155127143 via openalex
- W2155712529 via openalex
- W2163690533 via openalex
Cited by (22)
- Nuclear factor IX promotes endometriosis progression through transcriptional activation of tetraspanin-2 2026
- Expression of Toll-like Receptors on Lymphocyte Subpopulations and Their Soluble Forms in Serum and Urine of Women with Endometriosis 2025
- The role of fibrosis in endometriosis: a systematic review 2024
- Abordagem atual da endometriose: implicações patogênicas e terapêuticas 2024
- Immunological aspects of endometriosis: pathophysiological mechanisms, diagnosis, autoimmunity, targeted therapy and modulation 2024
- Immune and endocrine regulation in endometriosis: what we know 2023
- Understanding endometriosis from an immunomicroenvironmental perspective 2023
- The Role of Peritoneal Immunity in Peritoneal Endometriosis and Related Infertility 2023
- Cross-Talk between N6-Methyladenosine and Their Related RNAs Defined a Signature and Confirmed m6A Regulators for Diagnosis of Endometriosis 2023
- Blocking sphingosine 1-phosphate receptor 1 with modulators reduces immune cells infiltration and alleviates endometriosis in mice 2023
- Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives 2023
- Cross-Talk Between n6-Methyladenosine and Their Related RNAs Defined a Signature and Confirmed m6A Regulators for Diagnosis of Endometriosis 2022
- Immunopathogenesis of endometriosis: An overview of the role of innate and adaptive immune cells and their mediators 2022
- Endometriosis, the Silent Disease: Molecular Targets, Active Principles, and Drug Delivery Systems 2022
- Immune cells and Notch1 signaling appear to drive the epithelial to mesenchymal transition in the development of adenomyosis in mice 2021
- O inibidor Btk Ibrutinib limita o desenvolvimento da endometriose em camundongos 2021
- Immunosuppression and immunotherapy in endometriosis 2021
- B lymphocytes 2021
- New Therapeutics in Endometriosis: A Review of Hormonal, Non-Hormonal, and Non-Coding RNA Treatments 2021
- Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure 2020
- Immunological changes associated with adenomyosis: a systematic review 2020
- Evaluation of M1 and M2 macrophages in ovarian endometriomas from women affected by endometriosis at different stages of the disease 2019
Source provenance
- europepmc
- last seen: 2026-08-11T06:11:44.160905+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:22:41.077124+00:00
- unpaywall
- last seen: 2026-08-10T06:43:36.850308+00:00
License: CC0
· commercial use OK